Form 4: Neurocrine Biosciences Director Exercises Stock Options
SEC Form 4 Filing
Director George J. Morrow exercised stock options in Neurocrine Biosciences on May 17, 2024.
Summary
- On May 17, 2024, George J. Morrow, a director of Neurocrine Biosciences Inc., executed a transaction involving derivative securities.
- Morrow exercised 4,199 Restricted Stock Units (RSUs), each representing the right to receive one share of Neurocrine Biosciences' common stock.
- The RSUs were granted on May 17, 2023, and were fully vested at the time of the transaction.
- The transaction was reported on Form 4, filed with the SEC on May 21, 2024.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of an insider transaction and doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders, allowing investors to monitor their trading activity.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders.
- It provides transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 05/17/2023 | Date the Restricted Stock Units (RSUs) were granted to the Reporting Person |
| 05/17/2024 | Date of the transaction where the director exercised stock options. |
| 05/21/2024 | Date the Form 4 was signed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.